Pediatrics

In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.

The FDA approved the new round of vaccines for those 12 years and older and authorized emergency use for children 6 months to 11 years of age.

Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

The FDA has approved empagliflozin, and empagliflozin and hydrochloride to help manage type 2 diabetes in pediatric patients.

Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.

The FDA approved the first treatment for pediatric patients who experience functional constipation

The FDA has approved a treatment for Friedreich ataxia after the results of randomized, placebo-controlled study indicate a strong effectiveness in treatment.